Molecular etiology of Parkinson disease: Recent progress

Neuroscientist

Volumn 6, Issue 4, 2000, Pages 234-240

  Shastry, Barkur S ^a  

^a OAKLAND UNIVERSITY   (United States)

Author keywords

Degeneration; Lewy bodies; Mutation; Parkin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; BRAIN PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME P450; DOPAMINE; GLUTATHIONE TRANSFERASE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PARKIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUITIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; DEMENTIA; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; GENE MUTATION; GENE THERAPY; HEREDITY; HUMAN; LEWY BODY; NERVE DEGENERATION; NONHUMAN; NORTH AMERICA; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW;

EID: 0033865683     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385840000600406     Document Type: Review

References (98)

1. Manyam BV. Paralysis agitans and levodopa in Ayurveda: ancient Indian medical treatise. Mov Disord 1990;5: 47-8.
2. Wood N. Genes and parkinsonism. J Neurol Neurosurg Psychiatry 1997;62: 305-9.
3. Moghal S, Rajput AH, D'Arcy C, Rajput R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 1994;13:175-8.
4. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-9.
5. Fearnley JM, Lee AJ. Aging and Parkinson disease: substantia nigra and regional selectivity. Brain 1991;114: 2283-301.
6. Uhl GR, Walther D, Marsh D, Faucheux B, Javoy-Agid F. Dopamine transporter mRNA in the Parkinson disease and control of substantia nigra neurons. Ann Neurol 1994;35:494-8.
7. Aarsland D, Tandberg E, Larsen JP, Commings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996;53:538-42.
8. Lang AE, Lozano AM. Parkinson disease. N Engl J Med 1998;339:1044-53; 1130-42.
9. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson disease. Brain 1992;115:33-42.
10. Haas RH, Nasirian F, Nakano K. Low platelet mitochondrial complex I and Complex II/III activity in early untreated Parkinson disease. Ann Neurol 1995;37:714-22.
11. Kosel S, Grasbon-Frodl EM, Mautsch U, Egensperger R, Eitzen U, Frishman D, Hofmann S, Gerbitz K-D, Mehraein P, Graeber MB. Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease. Neurogenet 1998;1:197-204.
12. McNaught KS, Thullu U, Carrupt PA, et al. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol 1995;50:1903-11.
13. Hantraye P, Brouillet E, Feirante R, et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 1996;2:1017-21.
14. Przedborski S, Jackson-Lewis V, Yokoyama R, et al. Role of nitric oxide in MPTP-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 1996;93:4565-71.
15. Przedborski S, Kostic V, Jackson-Lewis V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992;12: 1658-67.
16. Nakao N, Frodl EM, Widner H, et al. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson disease. Nat Med 1995;1:226-31.
17. Cohen G, Farooqui R, Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci U S A 1997;94:4890-4.
18. Beck KD, Valverde J, Alexi T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy induced degeneration in the adult brain. Nature 1995;373:339-41.
19. Gash DM, Zhang ZM, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380:252-5.
20. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994;344:796-8.
21. Marttila RJ, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in Parkinson disease: increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurosci 1988;86:321-31.
22. Halliwell B, Gutteridge J. Oxygen radicals and the nervous system. Trends Neurosci 1985;8:22-6.
23. Schapira AHV. Evidence for mitochondrial dysfunction in Parkinson disease: a critical appraisal. Mov Disord 1994;9:125-38.
24. Ikeda H, Markey CJ, Markey SP. Search for neurotoxin structurally related to 1-methyl-4-phenyl pyridine in pathogenesis of Parkinson disease. Brain Res 1992;575:285-98.
25. Spina MB, Cohen G. Dopamine turn-over and glutathione oxidation: implication for Parkinson disease. Proc Natl Acad Sci U S A 1989;86:1398-400.
26. Ben-Shlomo Y. How far are we in understanding the cause of Parkinson disease. J Neurol Neurosurg Psychiatry 1996;61:4-16.
27. Tanner CM. The role of environmental toxins in the etiology of Parkinson disease. Trends Neurosci 1989;12:49-54.
28. Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson disease in Hong Kong. Neurology 1989;39:1314-18.
29. Bocchetta A, Corsini GU. Parkinson disease and pesticides. Lancet 1986;2:1163.
30. Senanayake N, Sanmuganathan PS. Extrapyramidal manifestations complicating organophosphorous insecticide poisoning. Hum Exp Toxicol 1995;14: 600-4.
31. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couter DG. Parkinson disease, pesticides and glutathione transferase polymorphisms. Lancet 1998;352:1344-6.
32. Semchuck KM, Love EJ, Lee RG. Parkinson disease and exposure to agricultural work and pesticide chemicals. Neurology 1992;42:1328-35.
33. McCann SJ, Pond SM, Le Couteur DG. The association between polymorphisms in the cytochrome P450 2D6 gene and Parkinson disease: a case control study and meta-analysis. J Neurosci 1997;153: 50-3.
34. Bandman O, Vaughan J, Holmans P, Marsden CD, Wood NW. Association of slow acetylator genotype for N-acetyltransferase-2 with familial Parkinson disease. Lancet 1997;350:1136-9.
35. Di Ilio C, Sacchetta P, Iannarelli V, Aceto A. Binding of pesticides to alpha, mu and pi class glutathione transferase. Toxicol Lett 1995;76:173-7.
36. Semchuk KM, Love EJ, Lee RG. Parkinson disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43:1173-80.
37. Tanner CM, Ottman R, Ellenberg JH. Parkinson disease: concordance in elderly male monozygotic and dizygotic twins. Neurology 1997;48(suppl):A333.
38. Bandman O, Marsden CD, Wood NW. Genetic aspects of Parkinson disease. Mov Disord 1998;13:203-11.
39. Duvoisin RC. Familial Parkinson disease. Neurosci News 1998;1:43-6.
40. Riess O, Jakes RA, Kruger R. Genetic dissection of familial Parkinson disease. Mol Med Today 1998;4:438-44.
41. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson disease. Science 1997;276:2045-7.
42. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson disease to chromosome 4q12-q23. Science 1996;274:1197-9.
43. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson disease maps to chromosome 2p13. Nat Genet 1998;18:262-5.
44. Matsumine H, Saito M, Shimoda MS, et al. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2-q27. Am J Hum Genet 1997;60:588-96.
45. Jones AC, Yamamura Y, Almasy L, et al. Autosomal recessive juvenile parkinsonism maps to 6q25.2-q27 in four ethnic groups: detailed genetic mapping of the linked region. Am J Hum Genet 1998;63:80-7.
46. Tassin J, Durr A, de Broucker T, et al. Chromosome 6 linked autosomal recessive early-onset parkinsonism: linkage in European and Algerian families, extension of the clinical spectrum and evidence of a small homozygous deletion in one family. Am J Hum Genet 1998;63:88-94.
47. Farrer M, Gwin-Hardy K, Muenter M, et al. A chromosome 4p haplotype segregating with Parkinson disease and postural tremor. Hum Mol Genet 1999;8:81-5.
48. Arai H, Maramatsu T, Higuchi S, Sasaki H, Trojanowski JQ. Apolipoprotein E gene in Parkinson disease with or without dementia. Lancet 1994;344:889.
49. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8.
50. Lucking CB, Abbas N, Durr A, et al. Homozygous deletion in parkin gene in European and north African families with autosomal recessive juvenile parkinsonism. Lancet 1998;352:1355-6.
51. Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum Mol Genet 1999;8:567-74.
52. Kruger R, Kuhn W, Muller T, et al. Ala 30 Pro mutation in the gene encoding alpha-synuclein in Parkinson disease. Nat Genet 1998;18:106-8.
53. Athanassiadou A, Voutsinas G, Psiouri L, et al. Genetic analysis of families with Parkinson disease that carry the Ala 53 Thr mutation in the gene encoding alpha-synuclein. Am J Hum Genet 1999;65:555-8.
54. Iwai A, Yoshimoto M, Masliah E, Saito T. Non-A beta component of Alzheimer disease amyloid (NAC) is amyloidogenic. Biochem 1995;34:10139-45.
55. Jenco JA, Rawlingson A, Daniels B, Morris AJ. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha-and beta-synucleins. Biochem 1998;37: 4901-9.
56. Maroteaux L, Scheller RH. The rat brain synucleins: family of proteins transiently associated with neuronal membrane. Mol Brain Res 1991;11:335-43.
57. Trojanowski JQ, Lee VM-Y. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies. Arch Neurol 1998;55:151-2.
58. Spillantin MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. Mutations in alpha-synuclein in Lewy bodies. Nature 1997;388:839-40.
59. Goedert M, Jakes R, Spillantini MG. Alpha-synuclein and the Lewy body. Neurosci News 1998;1:47-52.
60. Lendon CL, Ashall F, Goate AM. Exploring the etiology of Alzheimer disease using molecular genetics. JAMA 1997;277:825-31.
61. Hutton M, Hardy J. The presenilins and Alzheimer disease. Hum Mol Genet 1997;6:1639-46.
62. Hsiao K, Baker HF, Crow TJ, et al. Linkage of a prion protein missense variant to Gerstmann-Straussler-syndrome. Nature 1989;338:342-5.
63. Doh-ura K, Tateishi J, Kitamoto T, Sasaki H, Sakaki Y. Creutzfeldt-Jacob disease patients with congophilic kuru plaques have the missense variant prion protein common to Gerstmann-Straussler syndrome. Ann Neurol 1990;27:121-6.
64. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
65. Chase TN. A gene for Parkinson disease. Arch Neurol 1997;54:1156-7.
66. Scott WK, Staijich JM, Yamaoka LH, et al. Genetic complexities and Parkinson disease. Science 1997;277:387-8.
67. Wang WW, Kajavi M, Patel BJ, Beach J, Jankovic J, Ashizawa T. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian population. Arch Neurolog 1998;55: 1521-3.
68. Grasbon-Frodl EM, Kosel S, Riess O, Muller U, Mehraein P, Graeber MB. Analysis of mitochondrial targeting sequences and coding region polymorphism of the manganese superoxide dismutase gene in German Parkinson disease patients. Biochem Biophys Res Comm 1999;255:749-52.
69. El-agnat OMA, Jakes R, Curran MD, Wallace A. Effect of the mutation Ala30Pro and Ala53Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson disease. FEBS Lett 1998;440: 67-70.
70. El-agnat OMA, Jakes R, Curran MD, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta sheet and amyloid-like filaments. FEBS Lett 1998;440:71-5.
71. Narhi L, Wood SJ, Steavenson S, et al. Both familial Parkinson disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 1999;274:9843-6.
72. Wood SJ, Wypych WJ, Steavenson S, Louis J-C, Citron M, Biere AL. Alpha-synuclein fibrillogenesis is nucleation-dependent. J Biol Chem 1999;274:19509-12.
73. The French Parkinson disease genetic study group. Science 1998;279:1116-7.
74. Gibb WR, Lee AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson disease. Neuropathol Appl Neurobiol 1989;15:27-44.
75. Perry R, McKeith I, Perry E. Dementia with Lewy bodies: the second most common cause of dementia. Neurosci News 1998;1:28-35.
76. Orgel LE. The maintenance of the accuracy of protein synthesis and its relevance to aging. Proc Natl Acad Sci U S A 1963;49:517-21.
77. Jarman P, Wood N. Parkinson disease genetics comes of age. Br Med J 1999;318:1641-2.
78. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson disease. Nature 1998;395:451-2.
79. Alves-Rodrigues A, Gregori L, Figueiredo-Pereira ME. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci 1998;21:516-20.
80. Masliah E. The role of synaptic proteins in neurodegenerative disorders. Neurosci News 1998;1:14-20.
81. Welch WJ, Gambetti P. Chaperoning brain diseases. Nature 1998;392:23-4.
82. Schirmer EC, Lindquist S. Interaction of chaperone Hsp104 with yeast sup35 and mammalian PrP. Proc Natl Acad Sci U S A 1997;94:13932-7.
83. DebBerman SK, Raymond GJ, Caughey B, Lindquist S. Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci U S A 1997;94:13938-13.
84. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998;282:1914-17.
85. Wenning GK, Odin P, Morrish P, et al. Short and long term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson disease. Ann Neurol 1997;42:95-107.
86. Lindvall O, Patric B., Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor functions in Parkinson disease. Science 1990;247: 574-7.
87. Jiao S, Gurevich V, Wolff JA. Long term correction of rat model of Parkinson disease by gene therapy. Nature 1993;362: 450-3.
88. During MJ, Naegele JR, O'Malley KL, Geller AJ. Long-term behavioral recovery in Parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994;266:1399-1402.
89. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated viral vectors in the mammalian brain. Nat Genet 1994;8:148-53.
90. Horellu P, Brundin P, Kalen P, et al. In vivo release of Dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum. Neuron 1990;5:393-402.
91. Kang UJ. Potential for gene therapy for Parkinson disease: neurologic issues and new developments in gene transfer methodologies. Mov Disord 1998;13 (suppl): 59-72.
92. Fisher LJ, Jinnah H, Kale LC, Higgins GA, Gage FH. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-Dopa. Neuron 1991;6:371-80.
93. Dunnett SB, Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson disease. Nature 1999;399:A32.
94. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine and Parkinson disease. Lancet 1999;354:126-7.
95. Jankovic J. New and emerging therapies for Parkinson disease. Arch Neurolog 1999;56:785-90.
96. Schapira AHY. Parkinson disease. Br Med J 1999;318:311-14.
97. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins. JAMA 1999;281:341-6.
98. Jakes R, Spillantini MJ, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett 1994;345:27-32.